Over 90 Total Lots Up For Auction at One Location - WA 04/08

RaySearch and IBA expand their partnership in proton therapy

Press releases may be edited for formatting or style | October 27, 2021 Rad Oncology Proton Therapy
RaySearch and IBA have had a strategic partnership on a global level since 2013. Over the years the collaboration has deepened and the combination of RayStation®* and IBA’s Proteus® systems are nowadays a well proven and de facto industry standard. Today, the majority of IBA’s Proteus centers have selected RayStation as treatment planning system and in total 27 centers around the world are equipped with a Proteus proton delivery system in combination with RayStation.

As part of the collaboration, the RayCare®* oncology information system from RaySearch, will be customized for optimal use together with the IBA delivery solutions. In both RayStation and RayCare, as well as in the IBA delivery solutions, joint features, dedicated software interfaces and modified graphical user interface components will allow for a seamless integration of the workflow with optimized performance. The result will be a turnkey solution for all software and hardware needed to deliver outstanding proton therapy treatments.

The extended collaboration includes the following areas:

Proton ARC therapy planning in RayStation specific for DynamicARC®1: The next evolution in proton delivery, promising easy delivery scheme, decreased delivery times, and improved dose conformality.
FLASH treatment planning in RayStation for Conformal FLASH®2: Combines the benefits of FLASH radiotherapy with the dosimetric benefits of proton radiation and the Bragg Peak. FLASH radiotherapy has the potential to revolutionize the future of cancer treatment by delivering ultra-high dose rate radiation, several orders of magnitude higher than what is currently used in conventional clinical radiotherapy.
Machine specific treatment planning tools for moving tumors: Masters and guarantees the dose conformality along the treatment course for patients with moving tumors by exploiting the machine characteristics to its full potential and providing dedicated imaging processing capabilities.
Johan Löf, founder and CEO, RaySearch, says: “Today the combination of RaySearch’s RayStation and IBA’s Proteus is an industry standard within proton therapy. With the now announced expanded partnership between our companies, we aim to take proton therapy to the next level by developing several innovative radiotherapy technologies that will significantly improve patient care.”

Olivier Legrain, CEO of IBA, says: “We continue to demonstrate year after year that our combined expertise is providing superior integrated proton therapy solutions for the benefits of clinicians allowing them to take best care of their patients.”

You Must Be Logged In To Post A Comment